0513) (Supplementary Table 1). Anti-HPV-18 GMTs were still lower than control even when different adjuvant systems were used, though the 3-dose AS01 vaccine elicited the best anti-HPV-18 response out of the various tetravalent vaccine formulations tested. Anti-HPV-16 and -18 GMTs were significantly lower one month after the last vaccine dose when 2 doses (M0,3 or M0,6) of the AS01 formulation were administered,
compared with 3 doses of the same AS01 formulation. The results obtained for neutralizing antibodies measured by PBNA in a subset of subjects (Supplementary Fig. 1) were generally in line with those from ELISA testing, although numbers of subjects evaluated were small. In TETRA-051 (Fig. 2A), there was a significant impact of the HPV-31/45 dose on anti-HPV-31 and -45 GMTs. For groups with a 20 μg dose of HPV-31 and -45 L1 Kinase Inhibitor Library nmr VLPs (groups B, D and F combined), the estimated anti-HPV-31 GMT one month after the last vaccine dose was approximately 1.4-fold higher than for groups with a 10 μg dose (groups A, C and E combined) (12,667 [10,907, 14,711] versus 9173 [7867, 10,696] EU/mL; p = 0.0033) and the estimated anti-HPV-45 GMT was approximately 1.3-fold higher (7214
[6237, 8345] versus 5638 [4855, 6548] EU/mL; p = 0.0209). All tetravalent vaccine find more formulations elicited anti-HPV-31 and anti-HPV-45 GMTs that were at least 44-fold higher and 38-fold higher, respectively, than those associated with natural infection (i.e., 183.5 EU/mL for anti-HPV-31 and 139.0 EU/mL for anti-HPV-45) . In NG-001 (Supplementary Table 1), in women who were initially seronegative and HPV DNA negative for the corresponding HPV type, anti-HPV-33 GMTs were significantly higher one month after
the last vaccine dose for through the 3-dose AS01 vaccine (21,505 [17,842, 25,920] LU/mL) compared with AS02 (12,963 [10,846, 15,493] LU/mL, p = 0.0001) or AS04 (7102 [5869, 8595] LU/mL, p < 0.0001), with half the HPV-33/58 VLP content of the AS04 tetravalent formulation. Anti-HPV-58 GMTs were also significantly higher for the 3-dose tetravalent vaccine adjuvanted with AS01 (10,897 [9090, 13,064] LU/mL) compared with AS02 (6925 [5805, 8261] LU/mL, p = 0.0006) or AS04 (5524 [4556, 6698] LU/mL, p < 0.0001), with half the HPV-33/58 VLP content of the AS04 tetravalent formulation. For the AS01 formulation, anti-HPV-33 and -58 GMTs were significantly lower one month after the last vaccine dose when 2 doses (M0,3 or M0,6) were administered, compared with 3 doses. In Study NG-001, all tetravalent vaccine formulations produced cross-reacting anti-HPV-31, anti-HPV-45 and anti-HPV-52 GMTs which were at least 4-fold, 7-fold and 3-fold higher, respectively, than those associated with natural infection (i.e., 61.6 LU/mL for anti-HPV-31, 28.7 LU/mL for anti-HPV-45 and 54.